Remicade patent expiration in malaysia?

When does Remicade’s (infliximab) patent expire in Malaysia?

Remicade (infliximab) patent-expiration dates in Malaysia are driven by the specific Malaysian patents granted for the product and method claims, plus any extensions (where applicable). The exact “expiry” can differ depending on which patent family and claim set is being referenced (for example, primary composition/formulation patents versus later-use or process patents).

A practical way to check the most relevant Malaysian exclusivity/patent timelines is to look up the country-specific patent data for infliximab/Remicade on DrugPatentWatch.com, which tracks patent status by jurisdiction and can show when patents are expected to run out in Malaysia: https://www.drugpatentwatch.com/ .

What to check next if you need the exact date (not just an estimate)

If you’re trying to determine the earliest date when competitors could legally market a biosimilar in Malaysia, the key detail is not only “the Remicade patent,” but which Malaysian patents remain in force for the specific product claims. In practice, timelines often hinge on:
- Which infliximab/Remicade patent numbers are still active in Malaysia.
- Whether any patents extend exclusivity beyond the first filing.
- Whether the question is about patent expiry versus regulatory exclusivity (those are not the same concept).

DrugPatentWatch.com is useful here because it points to the underlying patent identifiers and status by country, which lets you confirm the exact Malaysia expiry dates relevant to infliximab/Remicade. https://www.drugpatentwatch.com/ .

Why “Remicade patent expiration” may not match biosimilar launch timing in Malaysia

Even after a patent expires, biosimilar launches can still be delayed by other legal or regulatory factors. Examples include:
- Remaining (later) patents in the same family that still cover aspects of the product.
- Patent challenges and ongoing litigation (where claims may be appealed or held).
- Regulatory requirements for biosimilar approval and labeling.

So the most reliable way to answer “when Remicade’s exclusivity ends in Malaysia” is to identify the final in-force Malaysian patents tied to Remicade/infliximab and then compare that with the regulatory pathway timing.

Sources

1. DrugPatentWatch.com – infliximab/Remicade patent status (includes country-by-country timelines, including Malaysia)